Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 1
2019 1
2020 1
2021 4
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?
Schiavetti I, Inglese M, Frau J, Signoriello E, Caleri F, Stromillo ML, Ferrò MT, Rilla MT, Gandoglia I, Gazzola P, Brichetto G, Pasquali L, Grimaldi L, Ulivelli M, Marinelli F, Cordera S, Clerico M, Conte A, Salvetti M, Battaglia MA, Franciotta D, Uccelli A, Sormani MP; CovaXiMS Study Group. Schiavetti I, et al. Eur J Neurol. 2023 Aug;30(8):2357-2364. doi: 10.1111/ene.15830. Epub 2023 May 28. Eur J Neurol. 2023. PMID: 37154406
Esrrb guides naive pluripotent cells through the formative transcriptional programme.
Carbognin E, Carlini V, Panariello F, Chieregato M, Guerzoni E, Benvegnù D, Perrera V, Malucelli C, Cesana M, Grimaldi A, Mutarelli M, Carissimo A, Tannenbaum E, Kugler H, Hackett JA, Cacchiarelli D, Martello G. Carbognin E, et al. Among authors: carlini v. Nat Cell Biol. 2023 May;25(5):643-657. doi: 10.1038/s41556-023-01131-x. Epub 2023 Apr 27. Nat Cell Biol. 2023. PMID: 37106060 Free PMC article.
Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy.
Najafi-Fard S, Petruccioli E, Farroni C, Petrone L, Vanini V, Cuzzi G, Salmi A, Altera AMG, Navarra A, Alonzi T, Nicastri E, Palmieri F, Gualano G, Carlini V, Noonan DM, Albini A, Goletti D. Najafi-Fard S, et al. Among authors: carlini v. Front Immunol. 2022 Sep 6;13:984098. doi: 10.3389/fimmu.2022.984098. eCollection 2022. Front Immunol. 2022. PMID: 36148228 Free PMC article.
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.
Sormani MP, Schiavetti I, Inglese M, Carmisciano L, Laroni A, Lapucci C, Visconti V, Serrati C, Gandoglia I, Tassinari T, Perego G, Brichetto G, Gazzola P, Mannironi A, Stromillo ML, Cordioli C, Landi D, Clerico M, Signoriello E, Cocco E, Frau J, Ferrò MT, Di Sapio A, Pasquali L, Ulivelli M, Marinelli F, Pizzorno M, Callari G, Iodice R, Liberatore G, Caleri F, Repice AM, Cordera S, Battaglia MA, Salvetti M, Franciotta D, Uccelli A; CovaXiMS study group. Sormani MP, et al. EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5. EBioMedicine. 2022. PMID: 35526306 Free PMC article.
18 results